0001599901-24-000172.txt : 20241023 0001599901-24-000172.hdr.sgml : 20241023 20241023161952 ACCESSION NUMBER: 0001599901-24-000172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241021 FILED AS OF DATE: 20241023 DATE AS OF CHANGE: 20241023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEVIN ARTHUR A CENTRAL INDEX KEY: 0001181556 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 241389457 MAIL ADDRESS: STREET 1: 1896 RUTHERFORD ROAD CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 125 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 4 1 wk-form4_1729714787.xml FORM 4 X0508 4 2024-10-21 0 0001599901 Avidity Biosciences, Inc. RNA 0001181556 LEVIN ARTHUR A C/O AVIDITY BIOSCIENCES, INC. 10578 SCIENCE CENTER DRIVE, SUITE 125 SAN DIEGO CA 92121 1 0 0 0 1 Common Stock 2024-10-21 4 M 0 5000 1.24 A 19830 D Common Stock 2024-10-21 4 S 0 5000 46.6335 D 14830 D Common Stock 131372 I By family trust Stock Option (Right to Buy) 1.24 2024-10-21 4 M 0 5000 0 D 2030-02-18 Common Stock 5000 3323 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $48.30. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. /s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact 2024-10-23